New GLA antibiogram!

Our 2017 antibiogram, which compiles antimicrobial resistance data from GLA isolates from the calendar year 2017 is now available here.  Overall resistance patterns are largely stable to slightly improved compared to 2016.  Notable findings include:

For Gram-negative rods in the hospital setting:

  • Amikacin remains the most active agent vs. multi-drug resistant Gram-negative rod infections at GLA.
  • Carbapenem-resistant Enterobacteriaceae remain somewhat uncommon at GLA.
  • There is not much overall difference between piperacillin-tazobactam, cefepime, and meropenem for most Enterobacteriaceae and Pseudomonas (but all are better than fluoroquinolones)
  • Pseudomonas is less frequently encountered in the urine as compared to other sites.

For Gram-negative rods in the outpatient setting:

  • Cepahlexin remains our first-line option for outpatient UTI treatment (the 92% susceptiblity rate of outpatient urinary E. coli to cefazolin may actually underestimate urinary cephalexin susceptibility as urinary breakpoints are higher than serum).
  • Fluoroquinolones and TMP-SMX susceptibility rates for urinary isolates are similar (~75-80%).

For Gram-positive rods:

  • MRSA remains common (~60% of nosocomial isolates and ~40% of outpatient isolates).
  • Doxycycline resistance is increasing among non-blood nosocomial S. aureus isolates (30%).